Periodic Reporting for period 2 - ENABLE (Advancing cell based therapies by supporting implant survival)
Reporting period: 2019-07-01 to 2020-12-31
1) A novel and highly controllable oxygen generating micromaterial that allows for long term oxygen release at physiologically relevant concentrations.
2) Creation of self-oxygenating tissues that were proven to survive and function following implantation.
3) We have been the first to demonstrate that – surprisingly – implant vascularization can be improved by increasing the implant’s oxygen tension.
4) We have developed the first fabrication strategy for ultra-high throughput of oxygen generating micromaterials.
5) We have developed the first 3D designed microfluidic droplet generator by exploring the use of 3D printing of microfluidic devices.
6) We have the developed a novel class of spatiotemporally controlled biomaterials based on macromolecular complex formation and displacement.
7) We developed a novel method to create and guide vascularization and angiogenesis by controlling the living implant’s microporosity with an unprecedented capillary density.
We expect that we will deliver the following results before the finalization of the project:
1) Enabling the fabrication of hierarchical blood vessel networks: smoothly going from a single large artery into a high density microcapillary bed that will converge back into a single vein.
2) Gaining fundamental insights into what drives cell death and implant failure following implantation and how this could be rescued to enable survival and function of implanted engineered tissues.
3) Creation of engineered clinically sized organs that will remain viable for at least three weeks in the absence of host nutrients to enable the in growth of the host vasculature.